Skip to content
Buy This GLP
← Research
Safety

GLP-1 Prescribing Around Pregnancy: US Trends From 2019 to 2024

Recorded semaglutide or tirzepatide prescribing increased in the years before and after delivery across U.S. delivery groups from 2019 to 2024.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team3 min read
People with a prescription per 1,000 deliveries2019 → 2024year before delivery0.26.4year after delivery0.314.6Rate of people with a prescription record.

The U.S. label guidance on planning a pregnancy depends on the product and why it is used. This study asked how often semaglutide or tirzepatide prescriptions were recorded around delivery [1].

What the study counted

Researchers used TriNetX records for U.S. patients ages 25 to 50 with documented deliveries. They measured whether each person had at least one prescription for either drug in the year before or the year after delivery [1].

In delivery groups from 2019 to 2024, the predelivery rate rose from 0.2 to 6.4 per 1,000 deliveries. The postdelivery rate rose from 0.3 to 14.6 per 1,000. The rates count people with at least one recorded prescription within the relevant window.

What the timing leaves unresolved

The year before delivery can include time before conception. A recorded prescription cannot establish whether someone used the medicine or when they took it.

The study did not compare pregnancy or infant outcomes. The rates show how prescribing changed in these records and cannot establish safety in pregnancy or while breastfeeding.

Frequently asked

Does predelivery prescribing mean the medicine was taken during pregnancy?
The 365-day window can include time before conception. A prescription record does not establish when or whether the drug was taken.
How common was prescribing after delivery?
By 2024, 14.6 people per 1,000 deliveries had at least one semaglutide or tirzepatide prescription recorded in the following year.

Sources

  1. [1] Lessard C, Cary C, In A, Steinle J, et al. (2026). Prescribing Trends in Glucagon-Like Peptide-1 Medications Among Pregnant and Postpartum Persons Obstetrics and Gynecology. PMID 41505759

More in Safety